Cleared Traditional

K072695 - VITEK 2 GRAM POSITIVE TIGECYCLINE (FDA 510(k) Clearance)

Nov 2007
Decision
53d
Days
Class 2
Risk

K072695 is an FDA 510(k) clearance for the VITEK 2 GRAM POSITIVE TIGECYCLINE. This device is classified as a System, Test, Automated, Antimicrobial Susceptibility, Short Incubation (Class II - Special Controls, product code LON).

Submitted by bioMerieux, Inc. (Hazelwood, US). The FDA issued a Cleared decision on November 16, 2007, 53 days after receiving the submission on September 24, 2007.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.1645.

Submission Details

510(k) Number K072695 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 24, 2007
Decision Date November 16, 2007
Days to Decision 53 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code LON — System, Test, Automated, Antimicrobial Susceptibility, Short Incubation
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.1645

Similar Devices — LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation

All 25
VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)
K251579 · bioMerieux, Inc. · Aug 2025
BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)
K251713 · Becton, Dickinson and Company · Aug 2025
BD Phoenix™ Automated Microbiology System - GN Imipenem-relebactam (0.0625/4 - 16/4 µg/mL)
K250447 · Becton, Dickinson and Company · May 2025
VITEK COMPACT PRO
K234012 · bioMerieux, Inc. · Mar 2025
BD Phoenix™ Automated Microbiology System
K250344 · Becton, Dickinson and Company · Mar 2025
BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL)
K233986 · Becton, Dickinson and Company · Mar 2024